A Phase 2, Open-label, Multicenter Study of PSMA ADC in Subjects With Metastatic Castration-resistant Prostate Cancer
Latest Information Update: 07 Nov 2021
At a glance
- Drugs PSMA ADC (Primary)
- Indications Prostate cancer
- Focus Therapeutic Use
- Sponsors Progenics Pharmaceuticals
- 26 Feb 2015 According to a Progenics Pharmaceuticals media release, results were presented at the American Society of Clinical Oncology Genitourinary Cancers (ASCO GU) Symposium.
- 26 Feb 2015 Results were published in a Progenics Pharmaceuticals media release.
- 23 Feb 2015 Status changed from active, no longer recruiting to completed, as per Progenics Pharmaceuticals media release.